JP2024506847A5 - - Google Patents
Info
- Publication number
- JP2024506847A5 JP2024506847A5 JP2023546266A JP2023546266A JP2024506847A5 JP 2024506847 A5 JP2024506847 A5 JP 2024506847A5 JP 2023546266 A JP2023546266 A JP 2023546266A JP 2023546266 A JP2023546266 A JP 2023546266A JP 2024506847 A5 JP2024506847 A5 JP 2024506847A5
- Authority
- JP
- Japan
- Prior art keywords
- aml
- pharmaceutical
- drug
- leukemia
- vivo inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015025A JP2025065209A (ja) | 2021-02-01 | 2025-01-31 | がんを処置および改善するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144378P | 2021-02-01 | 2021-02-01 | |
| US63/144,378 | 2021-02-01 | ||
| PCT/US2022/014663 WO2022165398A1 (en) | 2021-02-01 | 2022-02-01 | Methods for treating and ameliorating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015025A Division JP2025065209A (ja) | 2021-02-01 | 2025-01-31 | がんを処置および改善するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506847A JP2024506847A (ja) | 2024-02-15 |
| JP2024506847A5 true JP2024506847A5 (enExample) | 2025-02-10 |
Family
ID=82654982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546266A Pending JP2024506847A (ja) | 2021-02-01 | 2022-02-01 | がんを処置および改善するための方法 |
| JP2025015025A Pending JP2025065209A (ja) | 2021-02-01 | 2025-01-31 | がんを処置および改善するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015025A Pending JP2025065209A (ja) | 2021-02-01 | 2025-01-31 | がんを処置および改善するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240148688A1 (enExample) |
| EP (1) | EP4284519A4 (enExample) |
| JP (2) | JP2024506847A (enExample) |
| CN (1) | CN116829142A (enExample) |
| AU (1) | AU2022214463A1 (enExample) |
| CA (1) | CA3206959A1 (enExample) |
| WO (1) | WO2022165398A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254465A2 (en) * | 2023-06-09 | 2024-12-12 | The Regents Of The University Of California | Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04352783A (ja) * | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | １２員環マクロライド系化合物 |
| US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| WO2005063156A1 (en) | 2003-12-22 | 2005-07-14 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
| JP3903061B2 (ja) | 2003-12-24 | 2007-04-11 | 株式会社Ｌｔｔバイオファーマ | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| WO2006014035A1 (en) | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| WO2006044986A1 (en) | 2004-10-18 | 2006-04-27 | Nitto Denko Corporation | Intracellular peptide delivery |
| CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| WO2007110704A2 (en) * | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide compositions as therapeutic agent |
| NZ713868A (en) * | 2013-04-08 | 2021-12-24 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| WO2017053887A1 (en) * | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Methods for detection and eradication of myeloid leukemia stem cells |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| WO2022159760A1 (en) * | 2021-01-22 | 2022-07-28 | The Regents Of The University Of California | Methods for treating and ameliorating cancer |
-
2022
- 2022-02-01 CN CN202280012882.6A patent/CN116829142A/zh active Pending
- 2022-02-01 WO PCT/US2022/014663 patent/WO2022165398A1/en not_active Ceased
- 2022-02-01 AU AU2022214463A patent/AU2022214463A1/en active Pending
- 2022-02-01 US US18/275,388 patent/US20240148688A1/en active Pending
- 2022-02-01 CA CA3206959A patent/CA3206959A1/en active Pending
- 2022-02-01 JP JP2023546266A patent/JP2024506847A/ja active Pending
- 2022-02-01 EP EP22746855.0A patent/EP4284519A4/en active Pending
-
2025
- 2025-01-31 JP JP2025015025A patent/JP2025065209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12150942B2 (en) | Cerdulatinib for treating myeloma | |
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| CN110536702A (zh) | 使用hsp90抑制剂治疗癌症的方法 | |
| EP3703755B1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer | |
| AU2021200370B2 (en) | Boron-containing proteasome inhibitors for use after primary cancer therapy | |
| CA2806614A1 (en) | Combinatory cancer treatment | |
| JP2023080357A (ja) | リンパ球悪性疾患を治療するための方法 | |
| EP4252774A1 (en) | Combination therapy for treating pik3ca-mutated cancer | |
| JP2021528496A5 (enExample) | ||
| TW202529759A (zh) | 治療癌症之方法 | |
| US10342817B2 (en) | Combination therapy using ribavirin as elF4E inhibitor | |
| JP2024506847A5 (enExample) | ||
| CN114728003B (zh) | 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| MXPA06013902A (es) | Procedimiento para tratar el crecimiento de celulas anormal. | |
| TW202408485A (zh) | 用於減少癌症治療中不良副作用之組合物及方法 | |
| Cheson | New drug development in non-Hodgkin lymphomas | |
| US20220313718A1 (en) | New therapy and new therapeutic agent for blood cancer | |
| CN116509865A (zh) | 硝酮类化合物在制备预防或治疗骨髓抑制药物中的应用 | |
| JP2026502548A (ja) | 光学活性なアザビシクロ環誘導体を含むがんの治療剤 | |
| HK1255871B (en) | Cerdulatinib for treating myeloma | |
| MX2011009305A (es) | Composiciones y metodos para tratar sindrome mielodisplasico. | |
| WO2013019221A1 (en) | Compositions and methods for treating myelodysplastic syndrome |